Sangamo Therapeutics Announces Participation At Upcoming Investor and Industry Conferences

September 24, 2018 at 4:15 PM EDT

RICHMOND, Calif., Sept. 24, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that management will participate in the following healthcare investor and industry conferences in September and October.

  • 2018 Jefferies Gene Therapy Summit, New York, NY, September 27, 2018
    Sangamo's presentation is scheduled for 2:05 p.m. ET on Thursday.
  • Cantor Fitzgerald 2018 Global Healthcare Conference, New York, NY, October 1-3, 2018
    Sangamo's presentation is scheduled for 12:15 p.m. ET on Tuesday, October 2nd.
  • ARM Cell & Gene Meeting on the Mesa, La Jolla, CA, October 3-5, 2018
    Sangamo's presentation is scheduled for 3:15 p.m. PT on Wednesday, October 3rd. Earlier that day, Sandy Macrae, CEO of Sangamo, is also scheduled to participate in a panel discussion titled, "Spotlight: Commercializing Gene Therapies for Hemophilia" at 10:45 a.m. PT.
  • 2018 Chardan Genetic Medicines Conference, New York, NY, October 9, 2018
    Sangamo's presentation is scheduled for 3:15 p.m. ET on Tuesday.

Sangamo Therapeutics, Inc. (PRNewsfoto/Sangamo Therapeutics, Inc.)

The presentations will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentations will be archived on the Sangamo website for two weeks after the events.

About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo, visit www.sangamo.com.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/sangamo-therapeutics-announces-participation-at-upcoming-investor-and-industry-conferences-300717740.html

SOURCE Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc., McDavid Stilwell, 510-970-6000, x219, mstilwell@sangamo.com; Varant Shirvanian, 510-970-6000 x205, vshirvanian@sangamo.com